# RDD Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rdd-pharma

- Industry: Pharmaceuticals
- Headquarters: Tel Aviv-Yafo, Israel
- Website: www.rddpharma.com
- Total disclosed funding: $17M
- Latest round: Series B (Nov 16, 2017)
- Investors on record: 3

## About

RDD Pharma, Ltd. is a biopharmaceutical company focused on developing innovative therapeutics for anorectal diseases and gastrointestinal disorders, aiming to enhance patient outcomes with specialized drug-delivery systems.Founded in 2008 and headquartered in Tel Aviv-Yafo, Israel, RDD Pharma specializes in therapeutics for anorectal conditions. The company has undergone strategic pivots to enhance its focus on innovative drug delivery. With a total of 3 deals, RDD Pharma's latest funding round was a Series B in November 2017, where they raised USD 9.5 mn led by Pharmascience, joined by Capital Point and OrbiMed Advisors.RDD Pharma specializes in the development and commercialization of innovative therapeutics targeting anorectal diseases and gastrointestinal disorders. Their core product includes the Capository™, a proprietary drug-delivery system aimed at treating fecal incontinence and pruritus ani, along with a pharmaceutical compound for radiation proctitis currently in preclinical development. The company utilizes a high-reward, low-risk business model by repurposing approved drugs, catering primarily to healthcare providers in the United States and Europe.RDD Pharma's revenue model is structured around partnerships and direct sales to healthcare providers, focusing on specialized therapeutics. They engage in direct agreements with hospitals and clinics to provide their drug-delivery systems and pharmaceuticals. Their commercial strategy is centered on B2B sales, with the Capository™ and repurposed drugs forming the core of their offerings.Following the recent Series B financing of USD 9.5 mn on November 16, 2017, RDD Pharma plans to utilize the funds to advance their drug development pipeline and expand operations. The company aims to introduce upcoming products to address unmet needs in anorectal treatments and explore entry into new markets, particularly in additional European regions by 2022.

## Funding rounds

- Series B, Nov 16, 2017, $9.5M — OrbiMed Advisors, Pharmascience, Capital Point
- Series A, Jul 8, 2012, $7.2M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Pharmascience — Series B
- Capital Point — Series B